Concepedia

Sriram Subramaniam

SS

Statistics

Publications

18

Citations

1.9K

H-Index

18

Active since

1983

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Merck & Co., Inc., Rahway, NJ, USA (United States)

Roche (Switzerland)

Pharmaceutical Product Development (United States)

Sriram Subramaniam is an author at United States Food and Drug Administration specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1983–2023

18

Publications

18

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 292 citations · Full text

, , +16

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman et al. · Clinical Cancer Research · 2022 · 220 citations · Full text

, , +17

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Erin Larkins, Gideon M. Blumenthal, Weishi Yuan et al. · The Oncologist · 2017 · 216 citations · Full text

, , +16

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 138 citations

, , +11

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Donna Przepiorka, Lola Luo, Sriram Subramaniam et al. · The Oncologist · 2019 · 132 citations · Full text

, , +10

1–5 of 18